脉络通瘀汤治疗脱疽气虚血瘀证对气体信号分子的影响及疗效观察
|
摘要
闭塞性动脉硬化(atherosclerosis obliterans, ASO)是血管外科常见病、高发病,在中医外科属“脱疽”范畴。中医药对脱疽病诊疗有着悠久的历史,中药对脱疽病的治疗也在不断发展,但针对脱疽病中药干预与气体信号分子相关性的研究较少。本文主要包括脱疽与益气活血法及闭塞性动脉硬化与气体信号分子、脉络通瘀汤治疗脱疽气虚血瘀证疗效观察、脉络通瘀汤对闭塞性动脉硬化大鼠气体信号分调节作用三个部分。
第一部分文献综述。阐述了脱疽病因病机及益气活血法治疗脱疽的相关文献研究；闭塞性动脉硬化的现代医学研究、气体信号分子与动脉硬化性疾病的相关文献研究。
第二部分实验研究。研究脉络通瘀汤对脱疽气虚血瘀证大鼠模型干预作用与气体信号分子的调节机制。
方法：
50只大鼠以随机法分为空白对照组(A)10只、模型组(B)10只、低剂量治疗组(C)10只,中剂量治疗组(D)10只、高剂量治疗组(E)10只。采用高脂喂养、饥饿、疲劳复合因素复制大鼠脱疽气虚血瘀证模型。实验周期12周。
观察气虚血瘀证模型大鼠形态、症候学变化。
应用导师庞鹤教授临床验方脉络通瘀汤,治疗组分低(1g/Kg)、中(2g/Kg)、高(3g/Kg)剂量进行给药治疗。给药4周。
监测一般指标：凝血功能、血脂、血糖、肝肾功能等,评价安全性。评价疗效。
色谱法测定检测气体信号分子H2S、NO、iNOS含量。
放射免疫分析法检测血管舒缩活性物质ET、VEGF的表达。
观察组织病理学改变。
结果：
脉络通瘀汤对闭塞性动脉硬化症大鼠LDL、GLU影响,与正常对照组比较,模型组大鼠LDL、GLU显著升高,有差异；随治疗剂量增加,GLU呈递减趋势并最终恢复到正常水平,治疗高剂量组与模型组比较呈显著差异；LDL虽无明显递减趋势,但均恢复到对照组正常水平及以下,变化指标统计差异有显著性。
脉络通瘀汤对闭塞性动脉硬化大鼠H2S的影响：与正常对照组比较,模型组大鼠H2S降低,有差异；随治疗剂量增加,H2S呈递曾趋势,动脉匀浆中相关指标也呈同样趋势；高剂量组与模型组比较呈差异显著。
脉络通瘀汤对闭塞性动脉硬化大鼠ET、VEGF的影响,与正常对照组比较,模型组大鼠血浆中ET、VEGF、动脉血管匀浆中ET值具统计学意义；与模型组对比,治疗组随治疗剂量增加,血浆中ET、动脉血管匀浆中ET值均呈递减趋势,血浆中VEGF值呈递增趋势,各组数据变化统计差异有显著性。
结论：
通过高脂喂养、饥饿、疲劳的复合因素方法,可实现复制大鼠脱疽气虚血瘀证模型。
脱疽气虚血瘀证模型大鼠,形态学表现出毛色变暗、枯干、体重增长率下降、运动能力减弱等；证候学表现进食少、反应迟缓、爪甲、尾色紫暗等。
益气活血法治疗脱疽气虚血瘀证模型大鼠,改善脏腑功能,调节机体糖、脂代谢,可降低LDL、GLU,控制AS危险因素。
闭塞性动脉硬化病变形成,H2S呈降低趋势；中药益气活血治疗后H2S呈升高表现,提示H2S生物学效应可能为益气活血中药治疗脱疽的内在机制。
ET是较早发现的血管内皮细胞产生并分泌释放的长效血管收缩剂,VEGF作为一种广泛应用于临床治疗的内皮源性生长因子,能促进肢体侧枝循环的建立,本文研究表明,益气活血法治疗脱疽气虚血瘀证模型大鼠,可降低血浆ET含量、升高血浆VEGF表达。
气虚血瘀为本病的始动因素、基础病机,益气活血法为治疗本病的主要立法。益气活血法是现代中医药治疗动脉硬化性疾病的重要立法,应用益气活血立法组方的脉络通瘀汤,体现了“气为血帅,血为气母,气行则血行,气滞则血瘀”的中医学经典理论。
第三部分疗效观察。进行导师庞鹤教授经验方脉络通瘀汤对脱疽气虚血瘀证临床疗效观察。
参考《中国中西医结合学会周围血管疾病专业委员会1995年制订的诊断标准》、《中医病证诊断疗效标准》(ZY/T001.2-94),观察对象为北京中医药大学附属东方医院2013年3月-12月诊疗的60名患者。证候诊断为气虚血瘀、脉络瘀阻证。
治疗方案：基础治疗：注射用血塞通、内科病治疗；对照组治疗方案：仅予基础治疗；中药组治疗方案：基础治疗+中药治疗(方选脉络通瘀汤：黄芪60g、三七12g、牛膝10g、桂枝12g、泽兰20、地龙10g)。
疗效评价参考脱疽临床路径验证方案中评价标准。结果：按中华全国中医学会脉管专业委员会制订的疗效标准判定。治愈：对照组3例(10.00%),中药组4例(13.33%)；显效：对照组12例(40.00%),中药组16例(53.33%)；有效：对照组14例(46.67%),中药组10例(33.33%)；无效：1例(3.33%)为对照组。
对照组治疗评分与脉络通瘀汤组对比,在临床麻木、冷感改善方面有显著差异。讨论：早期诊断、早期治疗,应用益气活血法为指导的脉络通瘀汤对脱疽气虚血瘀证的治疗明确临床价值。
Arteriosclerosis obliterans (ASO) is a common disease with high prevalence in vascular surgery. In traditional Chinese medicine (TCM) surgery, the disease is categorized under the area of "digital gangrene". TCM has a long history in diagnosis and treatment of digital gangrene, and its Chinese medicine treatment has been consistently developing over the ages. However, research targeted at digital gangrene TCM intervention and its correlation with gaseous signaling molecules is relatively few. In this study, our objectives can be concluded into three main sections:1) studying the correlation between digital gangrene and replenishing qi activating blood method, as well as the correlation between ASO and gaseous signaling molecules,2) observation of therapeutic efficacy in the treatment of qi deficiency blood stasis pattern using vessel collateral dredging stasis decoction,3) observation of the regulatory effects of vessel collateral dredging stasis decoction on gaseous signaling molecules in ASO rats.
The first section: literature review. Literature related to digital gangrene's disease cause and mechanism of disease, treatment of digi tal gangrene using qi replenishing blood activating method, modern medical research on ASO, relationship between gaseous signaling molecules and arteriosclerotic disease were reviewed.
The second section: experimental research. Research on vessel collateral dredging stasis decoction's intervening effects in qi deficiency blood stasis pattern rat models, and its regulatory mechanism on gaseous signaling molecules were conducted.
Methods:
50lab rats were randomly distributed into5groups: blank control group (A),10rats; model group (B),10rats; low dosage treatment group (C),10rats; middle dosage treatment group (D),10rats; high dosage treatment group (E),10rats. The rats were subjected to composite factors comprising high-fat diet, starvation and fatigue in order to construct qi deficiency blood stasis rat models. Experimental period was set as12weeks.
Observation of morphology and symptomatology changes in qi deficiency blood stasis rat models.
Using the vessel collateral dredging stasis decoction, a clinically proven formula by Professor Pang He, rats from the respective treatment groups were administered with low dosage (1g/Kg), middle dosage (2g/Kg) and high dosage (3g/Kg) drug treatments accordingly. Drug treatment was administered for a period of4weeks.
Monitoring of general indicators:
Blood coagulation function, blood lipid level, blood glucose (GLU) level, liver function and kidney function were monitored. The results were then used as indicators for safety evaluation. Therapeutic effect was also evaluated.
Chromatography was used to detect content of gaseous signaling molecules hydrogen sulphide (H2S), nitric oxide (NO) and inducible nitric oxide synthase (iNOS).
Radioimmunoassay analysis was used to detect expression of vasoactive substances endothelin (ET) and vegetative growth factor (VEGF)Histopathological changes were observed.
Results:
Effects of vessel collateral dredging stasis decoction on low density lipoprotein (LDL) and blood GLU levels in ASO rats:Compared to the blank control group, significant increase in LDL and blood GLU levels were observed in model group rats. Difference in LDL and blood GLU levels was statistically significant. As drug dosage increases, progressive decrease in blood GLU levels eventually leading to normal levels was observed. Significant difference was observed between the high dosage treatment group and model group. Although no significant progressive decrease was observed for LDL levels, LDL levels in all three treatment groups recovered to normal or lower than normal levels. Statistical analysis of its change indicator revealed significant difference.
Effects of vessel collateral dredging stasis decoction on H2S levels in ASO rats:Compared to the blank control group, a significantly different decrease in H2S levels was observed in model group rats. As the drug dosage increases, progressive increase in H2S was observed, along with a similar increasing trend in related indicators from the artery homogenate. Difference between the high dosage treatment group and model group was statistically significant.
Effects of vessel collateral dredging stasis decoction on BT and VEGF levels in ASO rats:Compared to the blank control group, in blood serum ET, blood serum VEGF and artery homogenate ET levels in model group rats were statistically significant. Compared to the model group, progressive decrease was observed in blood serum and artery homogenate ET levels as drug dosage increased. Blood serum VEGF values however, displayed progressive increase as drug dosage increased. Significant difference was observed for change indicators in the data from each group.
Conclusion:
Through composite factor method using high-fat diet, starvation and fatigue, digital gangrene qi deficiency blood stasis rat models can be reproduced.
Digital gangrene qi deficiency blood stasis rat model:Morphology changes included darkening and drying up of fur, decrease in body weight increasing rate, weakening of exercise capacity etc. Symptomatology changes include decrease in food intake, slower response, and purplish-dark claw and tail coloration.
Treatment of digital gangrene qi deficiency blood stasis rats using qi replenishing blood activating method improves its organ functions, regulates GLU and lipid metabolism, decreases LDL and blood GLU levels, and controls arteriosclerosis (AS) risk factors.
In ASO formation, H2S displays a decreasing trend. After TCM qi replenishing blood activating treatment, H2S levels increased, thereby suggesting that biological effects of H2S may be the intrinsic mechanism in qi replenishing blood activating TCM treatment of digital gangrene.
ET, a biological substance produced and secreted by vascular endothelial cells, is one of the early discovered long-acting vasoconstrictors. On the other hand, VEGF is a type of endothelial growth factor widely-used in clinical treatment, and is known to promote limb collateral circulation formation. In our study, we have shown that treatment of digital gangrene qi deficiency blood stasis rats using qi replenishing blood act ivat ing method can decrease blood serum ET levels, and increase blood serum VEGF expression.
Qi deficiency blood stasis is the initiating factor and fundamental disease mechanism in digital gangrene. Hence, qi replenishing blood activating method is the main method in treating this disease. Qi replenishing blood activating method is an important method in modern TCM treatment of arteriosclerotic diseases. Vessel collateral dredging stasis decoction, formulated under the therapeutic method of qi replenishing blood activating, reflects the classical TCM theory "Qi is the commander of blood, blood is the mother of qi, if qi moves then blood moves, if qi stagnates then blood stasis".
The third section:observation of therapeutic effect. Therapeutic effect of Professor Pang He's empirical formula, vessel collateral dredging stasis decoction, on digital gangrene qi deficiency blood stasis pattern was observed.
60patients from the Beijing university of Chinese medicine Dong Fang hospital that were admitted between March2013to December2013were diagnosed and observed under protocols referenced from "China Society of Chinese and Western integration medicine peripheral vascular disease Committee diagnostic standards set in1995" and "Standards of diagnosis and therapeutic effect for TCM diseases and patterns"(ZY/T001.2-94). The patients admitted into our study group had been diagnosed with either qi deficiency blood stasis pattern or pattern of vessel collateral static blood obstruction.
Treatment plan: basic treatment: Xue Sai Tong (Notoginseng triterpenes) injection and internal medicine treatment; Control group treatment plan: only basic treatment was administered; Chinese medicine group treatment plan: basic treatment plan plus Chinese medicine treatment vessel collateral dredging stasis decoction was used: Milkvetch root60g, Sanqi12g, medicinal Cyathula root10g, Cassia twig12g, Hirsute shiny Bugleweed herb20g, Earthworm10g).
"Digital gangrene clinical verification scheme" was used as reference for therapeutic efficacy evaluation standards. Results: Therapeutic efficacy was evaluated using evaluation standards set by "Chinese National traditional Chinese medicine association blood vessel Committee". Healed:control group:3cases (10%), Chinese medicine treatment group:4cases (13.33%); significant effect:control group:12cases (40%), Chinese medicine treatment group:16cases (53.33%); effective:control group:14cases (46.67%), Chinese medicine treatment group:10cases (33.33%); non-effective:control group:1cease (3.33%).
Statistically significant difference was observed between treatment scores of the control group and vessel collateral dredging stasis decoction groups for improvements in clinical symptoms such as numbness and cold. Discussion: Early diagnosis, early treatment, and use of vessel collateral dredging stasis decoction, which uses qi replenishing blood activating method as a guideline, clearly has clinical value in treatment of digital gangrene qi deficiency blood stasis pattern.
第一部分文献综述。阐述了脱疽病因病机及益气活血法治疗脱疽的相关文献研究；闭塞性动脉硬化的现代医学研究、气体信号分子与动脉硬化性疾病的相关文献研究。
第二部分实验研究。研究脉络通瘀汤对脱疽气虚血瘀证大鼠模型干预作用与气体信号分子的调节机制。
方法：
50只大鼠以随机法分为空白对照组(A)10只、模型组(B)10只、低剂量治疗组(C)10只,中剂量治疗组(D)10只、高剂量治疗组(E)10只。采用高脂喂养、饥饿、疲劳复合因素复制大鼠脱疽气虚血瘀证模型。实验周期12周。
观察气虚血瘀证模型大鼠形态、症候学变化。
应用导师庞鹤教授临床验方脉络通瘀汤,治疗组分低(1g/Kg)、中(2g/Kg)、高(3g/Kg)剂量进行给药治疗。给药4周。
监测一般指标：凝血功能、血脂、血糖、肝肾功能等,评价安全性。评价疗效。
色谱法测定检测气体信号分子H2S、NO、iNOS含量。
放射免疫分析法检测血管舒缩活性物质ET、VEGF的表达。
观察组织病理学改变。
结果：
脉络通瘀汤对闭塞性动脉硬化症大鼠LDL、GLU影响,与正常对照组比较,模型组大鼠LDL、GLU显著升高,有差异；随治疗剂量增加,GLU呈递减趋势并最终恢复到正常水平,治疗高剂量组与模型组比较呈显著差异；LDL虽无明显递减趋势,但均恢复到对照组正常水平及以下,变化指标统计差异有显著性。
脉络通瘀汤对闭塞性动脉硬化大鼠H2S的影响：与正常对照组比较,模型组大鼠H2S降低,有差异；随治疗剂量增加,H2S呈递曾趋势,动脉匀浆中相关指标也呈同样趋势；高剂量组与模型组比较呈差异显著。
脉络通瘀汤对闭塞性动脉硬化大鼠ET、VEGF的影响,与正常对照组比较,模型组大鼠血浆中ET、VEGF、动脉血管匀浆中ET值具统计学意义；与模型组对比,治疗组随治疗剂量增加,血浆中ET、动脉血管匀浆中ET值均呈递减趋势,血浆中VEGF值呈递增趋势,各组数据变化统计差异有显著性。
结论：
通过高脂喂养、饥饿、疲劳的复合因素方法,可实现复制大鼠脱疽气虚血瘀证模型。
脱疽气虚血瘀证模型大鼠,形态学表现出毛色变暗、枯干、体重增长率下降、运动能力减弱等；证候学表现进食少、反应迟缓、爪甲、尾色紫暗等。
益气活血法治疗脱疽气虚血瘀证模型大鼠,改善脏腑功能,调节机体糖、脂代谢,可降低LDL、GLU,控制AS危险因素。
闭塞性动脉硬化病变形成,H2S呈降低趋势；中药益气活血治疗后H2S呈升高表现,提示H2S生物学效应可能为益气活血中药治疗脱疽的内在机制。
ET是较早发现的血管内皮细胞产生并分泌释放的长效血管收缩剂,VEGF作为一种广泛应用于临床治疗的内皮源性生长因子,能促进肢体侧枝循环的建立,本文研究表明,益气活血法治疗脱疽气虚血瘀证模型大鼠,可降低血浆ET含量、升高血浆VEGF表达。
气虚血瘀为本病的始动因素、基础病机,益气活血法为治疗本病的主要立法。益气活血法是现代中医药治疗动脉硬化性疾病的重要立法,应用益气活血立法组方的脉络通瘀汤,体现了“气为血帅,血为气母,气行则血行,气滞则血瘀”的中医学经典理论。
第三部分疗效观察。进行导师庞鹤教授经验方脉络通瘀汤对脱疽气虚血瘀证临床疗效观察。
参考《中国中西医结合学会周围血管疾病专业委员会1995年制订的诊断标准》、《中医病证诊断疗效标准》(ZY/T001.2-94),观察对象为北京中医药大学附属东方医院2013年3月-12月诊疗的60名患者。证候诊断为气虚血瘀、脉络瘀阻证。
治疗方案：基础治疗：注射用血塞通、内科病治疗；对照组治疗方案：仅予基础治疗；中药组治疗方案：基础治疗+中药治疗(方选脉络通瘀汤：黄芪60g、三七12g、牛膝10g、桂枝12g、泽兰20、地龙10g)。
疗效评价参考脱疽临床路径验证方案中评价标准。结果：按中华全国中医学会脉管专业委员会制订的疗效标准判定。治愈：对照组3例(10.00%),中药组4例(13.33%)；显效：对照组12例(40.00%),中药组16例(53.33%)；有效：对照组14例(46.67%),中药组10例(33.33%)；无效：1例(3.33%)为对照组。
对照组治疗评分与脉络通瘀汤组对比,在临床麻木、冷感改善方面有显著差异。讨论：早期诊断、早期治疗,应用益气活血法为指导的脉络通瘀汤对脱疽气虚血瘀证的治疗明确临床价值。
Arteriosclerosis obliterans (ASO) is a common disease with high prevalence in vascular surgery. In traditional Chinese medicine (TCM) surgery, the disease is categorized under the area of "digital gangrene". TCM has a long history in diagnosis and treatment of digital gangrene, and its Chinese medicine treatment has been consistently developing over the ages. However, research targeted at digital gangrene TCM intervention and its correlation with gaseous signaling molecules is relatively few. In this study, our objectives can be concluded into three main sections:1) studying the correlation between digital gangrene and replenishing qi activating blood method, as well as the correlation between ASO and gaseous signaling molecules,2) observation of therapeutic efficacy in the treatment of qi deficiency blood stasis pattern using vessel collateral dredging stasis decoction,3) observation of the regulatory effects of vessel collateral dredging stasis decoction on gaseous signaling molecules in ASO rats.
The first section: literature review. Literature related to digital gangrene's disease cause and mechanism of disease, treatment of digi tal gangrene using qi replenishing blood activating method, modern medical research on ASO, relationship between gaseous signaling molecules and arteriosclerotic disease were reviewed.
The second section: experimental research. Research on vessel collateral dredging stasis decoction's intervening effects in qi deficiency blood stasis pattern rat models, and its regulatory mechanism on gaseous signaling molecules were conducted.
Methods:
50lab rats were randomly distributed into5groups: blank control group (A),10rats; model group (B),10rats; low dosage treatment group (C),10rats; middle dosage treatment group (D),10rats; high dosage treatment group (E),10rats. The rats were subjected to composite factors comprising high-fat diet, starvation and fatigue in order to construct qi deficiency blood stasis rat models. Experimental period was set as12weeks.
Observation of morphology and symptomatology changes in qi deficiency blood stasis rat models.
Using the vessel collateral dredging stasis decoction, a clinically proven formula by Professor Pang He, rats from the respective treatment groups were administered with low dosage (1g/Kg), middle dosage (2g/Kg) and high dosage (3g/Kg) drug treatments accordingly. Drug treatment was administered for a period of4weeks.
Monitoring of general indicators:
Blood coagulation function, blood lipid level, blood glucose (GLU) level, liver function and kidney function were monitored. The results were then used as indicators for safety evaluation. Therapeutic effect was also evaluated.
Chromatography was used to detect content of gaseous signaling molecules hydrogen sulphide (H2S), nitric oxide (NO) and inducible nitric oxide synthase (iNOS).
Radioimmunoassay analysis was used to detect expression of vasoactive substances endothelin (ET) and vegetative growth factor (VEGF)Histopathological changes were observed.
Results:
Effects of vessel collateral dredging stasis decoction on low density lipoprotein (LDL) and blood GLU levels in ASO rats:Compared to the blank control group, significant increase in LDL and blood GLU levels were observed in model group rats. Difference in LDL and blood GLU levels was statistically significant. As drug dosage increases, progressive decrease in blood GLU levels eventually leading to normal levels was observed. Significant difference was observed between the high dosage treatment group and model group. Although no significant progressive decrease was observed for LDL levels, LDL levels in all three treatment groups recovered to normal or lower than normal levels. Statistical analysis of its change indicator revealed significant difference.
Effects of vessel collateral dredging stasis decoction on H2S levels in ASO rats:Compared to the blank control group, a significantly different decrease in H2S levels was observed in model group rats. As the drug dosage increases, progressive increase in H2S was observed, along with a similar increasing trend in related indicators from the artery homogenate. Difference between the high dosage treatment group and model group was statistically significant.
Effects of vessel collateral dredging stasis decoction on BT and VEGF levels in ASO rats:Compared to the blank control group, in blood serum ET, blood serum VEGF and artery homogenate ET levels in model group rats were statistically significant. Compared to the model group, progressive decrease was observed in blood serum and artery homogenate ET levels as drug dosage increased. Blood serum VEGF values however, displayed progressive increase as drug dosage increased. Significant difference was observed for change indicators in the data from each group.
Conclusion:
Through composite factor method using high-fat diet, starvation and fatigue, digital gangrene qi deficiency blood stasis rat models can be reproduced.
Digital gangrene qi deficiency blood stasis rat model:Morphology changes included darkening and drying up of fur, decrease in body weight increasing rate, weakening of exercise capacity etc. Symptomatology changes include decrease in food intake, slower response, and purplish-dark claw and tail coloration.
Treatment of digital gangrene qi deficiency blood stasis rats using qi replenishing blood activating method improves its organ functions, regulates GLU and lipid metabolism, decreases LDL and blood GLU levels, and controls arteriosclerosis (AS) risk factors.
In ASO formation, H2S displays a decreasing trend. After TCM qi replenishing blood activating treatment, H2S levels increased, thereby suggesting that biological effects of H2S may be the intrinsic mechanism in qi replenishing blood activating TCM treatment of digital gangrene.
ET, a biological substance produced and secreted by vascular endothelial cells, is one of the early discovered long-acting vasoconstrictors. On the other hand, VEGF is a type of endothelial growth factor widely-used in clinical treatment, and is known to promote limb collateral circulation formation. In our study, we have shown that treatment of digital gangrene qi deficiency blood stasis rats using qi replenishing blood act ivat ing method can decrease blood serum ET levels, and increase blood serum VEGF expression.
Qi deficiency blood stasis is the initiating factor and fundamental disease mechanism in digital gangrene. Hence, qi replenishing blood activating method is the main method in treating this disease. Qi replenishing blood activating method is an important method in modern TCM treatment of arteriosclerotic diseases. Vessel collateral dredging stasis decoction, formulated under the therapeutic method of qi replenishing blood activating, reflects the classical TCM theory "Qi is the commander of blood, blood is the mother of qi, if qi moves then blood moves, if qi stagnates then blood stasis".
The third section:observation of therapeutic effect. Therapeutic effect of Professor Pang He's empirical formula, vessel collateral dredging stasis decoction, on digital gangrene qi deficiency blood stasis pattern was observed.
60patients from the Beijing university of Chinese medicine Dong Fang hospital that were admitted between March2013to December2013were diagnosed and observed under protocols referenced from "China Society of Chinese and Western integration medicine peripheral vascular disease Committee diagnostic standards set in1995" and "Standards of diagnosis and therapeutic effect for TCM diseases and patterns"(ZY/T001.2-94). The patients admitted into our study group had been diagnosed with either qi deficiency blood stasis pattern or pattern of vessel collateral static blood obstruction.
Treatment plan: basic treatment: Xue Sai Tong (Notoginseng triterpenes) injection and internal medicine treatment; Control group treatment plan: only basic treatment was administered; Chinese medicine group treatment plan: basic treatment plan plus Chinese medicine treatment vessel collateral dredging stasis decoction was used: Milkvetch root60g, Sanqi12g, medicinal Cyathula root10g, Cassia twig12g, Hirsute shiny Bugleweed herb20g, Earthworm10g).
"Digital gangrene clinical verification scheme" was used as reference for therapeutic efficacy evaluation standards. Results: Therapeutic efficacy was evaluated using evaluation standards set by "Chinese National traditional Chinese medicine association blood vessel Committee". Healed:control group:3cases (10%), Chinese medicine treatment group:4cases (13.33%); significant effect:control group:12cases (40%), Chinese medicine treatment group:16cases (53.33%); effective:control group:14cases (46.67%), Chinese medicine treatment group:10cases (33.33%); non-effective:control group:1cease (3.33%).
Statistically significant difference was observed between treatment scores of the control group and vessel collateral dredging stasis decoction groups for improvements in clinical symptoms such as numbness and cold. Discussion: Early diagnosis, early treatment, and use of vessel collateral dredging stasis decoction, which uses qi replenishing blood activating method as a guideline, clearly has clinical value in treatment of digital gangrene qi deficiency blood stasis pattern.
引文
[1]张伯根等,慢性下肢动脉缺血性疾病诊疗面临的问题及发展趋势,中国实用外科杂志,1998,18(9)：518-519
[2]李小鹰,王洁,何耀,范利.周围动脉硬化闭塞症在老年血脂异常人群中的现患率调查[J].中华老年心脑血管病杂志2005,2.(7)：3-4.
[3]王玉琦,叶建荣.血管外科治疗学[M].上海：上海科学技术出版社2003：13
[4]张培华,将米尔主编,临床血管外科学(第二版),科学出版社,2007：403
[5]冯有贤主编,血管外科学(第二版),1992,上海科技出版社
[6]灵枢[M].北京：人民卫生出版社,956
[7]龚庆宣.刘涓子鬼遗方[M].北京：人民卫生出版社,1955.
[8]申斗垣.外科启玄[M].北京：人民卫生出版社,1955年排印本
[9]陈文治.疡科选粹[M].上海：新中华书社,1954.
[10]李日庆主编,《中医外科学》,2007,中国中医药出版社
[11]高思敬.外科医镜[M].北京：人民卫生出版社,1955.
[12]王清任.医林改错[M].北京：人民卫生出版社,1956
[13]高秉钧.疡科心得集[M].北京：人民卫生出版社,1955.
[14]顾伯华主编.实用中医外科学.上海科学技术出版社,1985,31.
[15]王凤歧主编.中华名医特级集成.中国中医药科技出版社,1993,468.
[16]陆德明.中医外科学[M].上海：上海科学技术出版社1997：6
[17]王巧萍,黄学阳.脱疽的古文献综述[J].中医研究,2004,17(1)：57-59.
[18]张伯根等,慢性下肢动脉缺血性疾病诊疗面临的问题及发展趋势,中国实用外科杂志,1998,18(9)：518-519.
[19]赵立军,等.脱疽痛证的机理及辨证探析.北京中医,1995,(3)：13.
[20]李翠娟,烟建华,攻振东.对中医证本质研究的反思.中国中医基础医学杂志.2005；11(4)：271-274.
[21]阎莉,吴圣贤.中医证本质研究思考.中国中西医结合杂志.2000；20(5)：383.
[22]包祖晓,刘素芝,张远怀.缺血性中风气虚血瘀证的客观化研究现状与展望.中华中医药学刊.2007；25(2)：295-298.
[23]王丽英,张宏敏,谢春光,等.中医释义动脉粥样硬化及2型糖尿病.时珍国医国药.2005；16(7)：662-664.
[24]尚德俊,王嘉桔,王书桂.中西医结合周围血管疾病学.海口：南海出社,1995：19-22.
[25]素问[M].北京：人民卫生出版社,1956.
[26]医林改错[M].上海：新中华书社,1954.
[27]素问[M].北京：人民卫生出版社,1956.
[28]鲍相敖.验方新编[M].天津：天津科学技术出版社,1991.
[29]汪机.外科理例[M].上海：商务印书馆,1957.
[30]王洪绪.外科证治全生集[M].北京：人民卫生出版社,1956.
[31]李晓亮,樊凯芳.益气活血法在闭塞性动脉硬化症中的应用[J].山西中医学院学报2006,3(5)：52-54.
[32]柳玉亭,等.中西医结合治疗闭塞性动脉粥样硬化69例.山东中医杂志1994；13(5)：211.
[33]王景春.辨证治疗肢体闭塞性动脉硬化症101例.辽宁中医杂志,1993,(11)：21.
[34]李廷来.中西医结合治疗闭塞性动脉硬化笔谈.山东医药,1984,(5)：31.
[35]宋景贵.中西医结合治疗86例闭塞性动脉硬化症的临床研究.山东中医杂志,1984,(2)：28.
[36]俞守艳,杨启发.当归四逆汤合阳和汤治疗肢端动脉硬化性闭塞症33例.实用中医药杂志,2004,20(10)：10.
[37]张建强.全元丹治疗动脉硬化性闭塞症的临床研究[J].河北中医,2001,2(12)：893-895.
[38]王书桂.益气活血法治疗动脉硬化性闭塞症的临床观察.山东中医杂志,1984,(4)：54.
[39]张氏医通[M].北京：人民卫生出版社,1956.
[40]王玉琦,叶建荣.血管外科治疗学[M].上海：上海科学技术出版社2003：11.
[41]张培华,将米尔主编,临床血管外科学(第二版),科学出版社,2007：431.
[42]王玉琦,叶建荣.血管外科治疗学[M].上海：上海科学技术出版社,2003：131.
[43]常恩坦,高桥保雄.小儿动脉粥样硬化[J].日本医学介绍,1989,10(3)：101.
[44]黄玉麟.儿童心血管疾病的危险因素[J].临床儿科杂志,1986,4(2)：85.
[45]赵亚朴.被动吸烟加速动脉粥样硬化[J].国外医学心血管分册,1999,26(1)：48.
[46]尚德俊,王嘉桔,王书桂,等.中西医结合实用周围血管疾病学[M].海口：南海出版公司,1995.179-256.
[47]Sacid B, Kryatyna TK, Juan CM,et al. Role of nitric oxide in the angiogenic response in vitro to bFGF[J]. Cire Res,1998,82(9):1007.
[48]金星,刘明,孟红等.肢体动脉粥样硬化闭塞症病毒感染相关性中医研究[J].山东中医药大学学报,2000,24(2)：101.
[49]陈瑞珍.巨细胞病毒感染与动脉粥样硬化关系的探讨[J].临床,1995,2(2)：79.
[50]冯宝根.动脉粥样硬化症与肺炎衣原体感染91例尸检结果报告[J].金陵医院学报,1999,12(2)：96.
[51]李永强,董吁钢.肺炎衣原体感染与动脉粥样硬化[J].新医学,2002,33(5)：309.
[52]Muhlestein J,AndersonJ,Hammond,et al,Infection with chlamydia pneumoniae acclerates the development of atherosclerosis and threatment with azithromycin prevents it a rabbit model[J]. Circulation,1998,97(7):633.
[53]王吉云.动脉粥样硬化与长期砷暴露有关[J].中国医学论坛报,2002,5(3)：21.
[54]李小鹰,王洁,何耀,范利.周围动脉硬化闭塞症在老年血脂异常人群中的现患率调查[J].中华老年心脑血管病杂志2005,2.(7)：3-4
[55]倪廷枢.动脉粥样硬化形成的现代观点,国外医学,老年医学分册；1997.18(1)P9.
[56]邓英姿.清道夫受体与AS关系的研究进展,国外医学,心血管疾病分册1997.24(5)P3.
[57]倪廷枢.动脉粥样硬化形成的现代观点,国外医学,老年医学分册,1997.18(1)P9.
[58]于光耀.血管内皮功能障碍与ASO中国动脉硬化杂志；1996.4(2)P145.
[59]R. ROSS Pathogenesis of atherosclerosis a perspective forthe 1990s Nature Vol 362.29 Apr1993.p801.
[60]危当恒,王贵学,黄华,刘录山,王佐,唐朝克.低密度脂蛋白对血管内皮细胞骨架及粘附能力的影响[J].医用生物学,2006,21,(6)：105-11
[61]马丽,朱文云,李宏妹,邢海燕,金永娟.OX-LDL对内皮细胞粘附分子表达及粘附功能影响的研究[J].微循环学杂志,2000.3(10)：49
[62]Sukhova GK,Babaev VR,Sirthkin Vn et al Phenotype change in smooth muscle cells or human coronary arteries during aging and during development of atherosclerosis Kardiologiia1991;31(8):15-19.
[63]Shanahan CM,Cary NR,Metcalfe JC,et al.High expression of gene for calcification regulary proteins in human athorosclerosis Plaques J Chin lnvest,1994;93(6):2393-2402.
[64]李建华,郭志刚,吴平生,杨永红,赖文岩.血管内皮细胞中ABCAI的表达及其在动脉粥样硬化发生中的意义[J].第一军医大学学报,2004,24,(9)：980-983
[65]Callow AD.Endothelial dysfunction Ⅰ natheroselerosis[J].Vascul Pharm acol,2002,38(5):257-258.
[66]Golino P,Piscione F,Willerson JT,et al.Divergent effects of serotonin on coronary artery dimensions and blood flow in Patients with coronary atheroselerosis and control patients[J].N Eng J Med,1991,324(10):641-648.
[67]LermanA,Holmes DR Jr,BellMR,et al.Endothel in incoronary endothelial dysfunetion and early atherosclerosis in humans[J].Clreulation,1995,92(9): 2426-2431.
[68]Geisler T,Bhatt DL.The role of inflammation in atherothrombosis:current and future strategies of medical treatment[J].MedSeiMonit,2004,10(12):RA308-316.
[69]Cybulsky M I,Iiyama K,Li H,et al.A major role for VCAM-1,but not ICAM-1, in early atherosclerosis[J].JClinInvest,2001,107(10):1255-1262.
[70]Boring L,Gosling J,Cleary M,et al.Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis[J]. Nature,1998,394(6696):894-897.
[71]Herman MP,Sukhova GK,Libby P,et al.ExPression of neutroPhil collage nase (matrixmetalloproteinase28) in human atheroma:a novel collagenolytic Pathway suggested by transcriptionalp rofiling[J]. Circulation,2001,104(16):1899-1904.
[72]Chamorro A.Role of inflanunation in stroke and atherothrombosis[J]. Cerebrovase D15,2004,17(Supp13):125.
[73]Becquemin JP,Favre JP,Marzelle J,et al.Systematic versusselective stent placement after superficial femoral artery balloonangioplasty:a multicenter prospective randomized study. J VascSurg,2003,37:487-494.
[74]Schillinger M,Exner M,Mlekusch W,et al.Inflammatory responseto stent implantation:differences in femoropoplitea, iliac,and carotidarteries.Radiology, 2002,224:529-535.
[75]Garasic JM,Creager MA.Percutaneous interventions for lowe extremity peripheral atherosclerotic disease.Rev Cardiovasc Med2001,2:120-125.
[76]Krishna K,Gary JB,MyriamHMG,et al.Transcatheter interventionfor the treatment of peripheral atherosclerotic lesions:Part Ⅰ.J VascInterv Radio 1,2001, 12:683-695.
[77]卢成志,David Ho,李玉光,等.髂动脉内支架植入术后临床及血管造影随访.介入放射学杂志,2002,11：182-183.
[78]Khodja HR, Sala F,Declemy S,et al.Value of stent placementduring percutaneous transluminal angioplasty of the iliac arteries. JCardiovasc Surg(Torino),2001,42:369-374.
[79]Robert MC, Ian LG,Jonathan MT,et al.Angioplasty and stent placement in chronic occlusion of the superficial femoral artery.technique and results. J Vase Interv Radiol,2000,11:1009-1020.
[80]Richard RS,Jeanine MC,Justin MG,et al.Long-term results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery:single center experience from a prospective, randomized trial.Cardiovasc Interv Radiol,2003, 14:303-311.
[81]CejnaM, Thurnher S,Illiasch H,et al.PTA versus Palmaz stent placement in femoropopliteal artery obstructions:a multicenter prospective randomized study. J Vasc Interv Radiol,2001,12:23-31.
[82]Pozzi Mucelli F, Fisicaro M,Calderan L,et al.Percutaneou revascularization of femoropopliteal artery disease.PTA plus stent Results after six years'follow-up. Radiol Med(Torino),2003,105339-349.
[83]Timaran CH,Stevens SL,FreemanMB,et al.Predictors for adverseoutcome after iliac angioplasty and stenting for limb-threateningischemia.J Vasc Surg,2002, 36:507-513.
[84]HenryM,Henry I,Klonaris C,et al.Clinical experience with the OptiMed sinus stent in the peripheral arteries.J Endovasc Ther,2003,10:772-779.
[85]金龙,邹英华,高健,等.慢性长段髂动脉闭塞的血管腔内成形治疗.中国医学影像技术,2001,17：1033-1045.
[86]Klinkert P.Schepers A,Burger DH,et al.Vein versus polytetraflu-oroethylene in above-knee femoropopliteal bypass grafting:five-yearresults of a randomized controlled trial[J].J Vase Surg,2003,37(1):149-155
[87]Ballotta E,Renon L,Toffano M,et al.Prospective randomized study onbilateral above-knee femoropopliteal revascularization:Polytetrafluo-roethylene graft versus reversed saphenous vein[J].J Vase Surg,2003,38(5):1051-1055.
[88]Sala F,Hassen-Khodja R,Lecis A,et al.Long-term outcome of femoral above-knee popliteal artery bypass using autologous saphenous vein versus expanded polytetrafluoroethylene grafts[J].Ann Vase Surg,2003,17(4):401-407.
[89]Mamode N,Scott RN.Graft type for femoro-popliteal bypass surgery [J].Cochrane Database Syst Rev,2000,(2):CD001487.
[90]Devine C,McCollum C.North West Femoro-Popliteal Trial Partici-pants. Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial[J].J Vase Surg,2004,40(5):924-931.
[91]ZhangQinyou, Du Junbao,ZhangQunyu, et al.Impact of endogenous nitric oxide on the hydrogen sulfide/cystathionine-y-lyase system in pulmonary hypoxic rats.J Appl Clin Pediatr,2003,18:865-867
[92]金红芳,杜军保,唐朝枢.气体信号分子在心血管疾病发病中的意义.中国医学科学院学报,2005；25(2)：518-524.
[93]杜军保,齐建光,石云,等,肺动脉高压形成机制中的气体信号分子网络,北京 大学学报(医学版)2002；34(5)：536-541
[94]耿彬,闫辉,钟光珍,等.硫化氢一心血管功能调节的新型气体信号分子,北京大学学报(医学版)2004；36(1)：106.
[95]曹建春,张东萍.中西医结合治疗糖尿病足.中医药学刊,2006,24(5)：858-859.
[96]Du JB,Yan H.Cheung Y,et al.Th e possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. Heart Vessels, 2004,19(2):75.
[97]欧阳秋芳,谢良地,苏津自.内源性H2S的生理、病理功能及其与NO、CO的相互作用,中国分子心脏病学杂志,2005,5(2)：503-506.
[98]谷万里,史载祥,气体信号分子与活血化瘀研究,中国中西医结合杂志,2006,36(3)：262-265.
[99]尹小川,刘健康,周序珑,等.三七总皂贰对培养的猪主动脉内皮细胞释放一氧化氮的影响[J].中国动脉硬化杂志,1996,4(1)：20-23.
[100]Lee SW,Hu Y S,Hu L F,et al.Hydrogen sulphide regulates calcium homeostasis in microglial ceils[J].Glia,2006.54(2):116-124.
[101]Ying-Yuan Pamela Mok,Mohammed Shirhan Bin Moham med Atan,Cbeong Yoke Ping,et al.Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect ofinhibitors of hydrogen sulphide biosynthesis[J].BT J Pharmacol,2004,143(7):881-889.
[102]Lee SW,Hu Y S,Hu L F,et al.Hydrogen sulphide regulates calcium homeostasis in microglial ceils[J].Glia,2006.54(2):116-124.
[103]ShiLin,Du Junbao, Qi Jianguang,et al.Effects of L-arginine on pathologic structure and endogenous hydrogen sulfide pathway in rats with pulmonary hypertension induced by high pulmonary blood flow.Basicmedical science and clinics,2004,24:184-187.
[104]Chen Xiaobo, Du Junbao, Gen bin. Changes in arterial hydrogen sulfide content during septic shock and endotoxin shock in rats. Basic medical science and clinics,2003,23:384-387.
[105]Marika Coilin, Farhana B M. Anuar, Oliver Murch, et al. Inhibition of endogenous hydrogen sulfideformation reduces the organ injury caused by endotoxemia[J].BT J Pharmacol,2005,146(4):498-505
[106]汪德清,沈文梅.黄茂三种提取成分对氧自由基作用的影响[J].中国药理学通报,1994,20(2)：129-132
[107]Warenycia MW,Goodwin LR,Benishin CC Reiffenstein RJ,Francom DM,Taylor JD,et al. Acute hydrogen sulfide poisoning. Demonstration of selective uptake of sulfide by the brainstem by measurement of brain sulfide levels. Biochem Phannacol 1989;38:973-981.
[108]Goodwin LR,Francom D,Dieken FP,Taylor JD, Warenycia MW,Reiffenstein RJ,et al. Determination of sulfide in brain tissue by gas dialysision chromatography:postnnortem studies and two case reports. J Anal Toxicol 1989;13:108-109.
[109]Vang R.Two's company,three's a crowd:can H2S be the third endogenous gaseous transmitter Faseb J 2002;16:1792-1798.
[110]Hao W,Zhang J,Lu Y,Wang R.The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener.Embo J 2001;20:6008-6016.
[111]Abe K,Kimura H.The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 1996;16:1066-1071.
[112]Hosoki R, Matsuki N,Kimura H.The possible role of drogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem Biophys Res Commun 1997;237:527-531.
[113]Kamoun P.Endogenous production of hydrogen sulfide in mammals. Amino Acids 2004;26:243-254.
[114]Zhao W,Ndisang JF,Wang R. Modulation of endogenous production of H2S in rat tissues. Can J P siol Pharmacol 2003;81:848-853.
[115]Chen P,Poddar R,Tipa EV,Dibello PM,Moravec CD,Robinson K,et al.Homocysteine metabolism in cardiovascular cells and tissues:implications for hype;rhomocysteinemia and cardiovascular disease.Adv Enzyme Regul 1993; 39:93-109.
[116]Tang C,Li X,Du J.Hydrogen sulfide as a new endogenous gaseous transmitter in the cardiovascular system. Curr Vasc Pharmacol 2006;4:17-22.
[117]Furne J,Springfield J,Koenig T,DeMaster E,Levitt MD.Oxidation of drogen sulfide and methanethiol to thiosulfate by rat tissues:a specialized function of the colonic mucosa.Biochem Pharmacol 2001;62:255-259.
[118]Geng B,Yang J,Qi Y,Zhao J,Pang Y,Du J,et al.H2S generated by heart in rat and its erects on cardiac function.Biochem Biophys Res Commun 2004; 313:362-368.
[119]Yang q Cao K,Wu L,Wang R.Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1 J Biol Chem 2004;279:49199-49205.
[120]Du J,Hui Y,Cheung Y,Bin C,Jiang H,Chen X,et al.The possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. Heart Vessels 2004;19:75-80.
[121]Gang q Sun X,Wang R.Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen-activated protein kinases and caspase-3.Faseb J 2004;18:1782-1784.
[122]Lieng B,Chang L,Pan C,Qi Y.Zhao J,Pang Y,et al.Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol.Biochem Biophys Res Commun 2004;318:756-763.
[123]Fivarajah A,McDonald MC, Thiemermann C.The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat. Shock 2006;26:154-161.
[124]Pan TT,Feng ZN,Lee SW,Moore PK, Bian JS.Endogenous hydrogen sulfide conltributes to the cardioprotection by metabolic inhibition preconditioning in the rat venl: ricular myocytes.J Mol Cell Cardiol 2006;40:119-130.
[125]Bolli R.Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research.J Mol Cell Cardiol 2001;33:1897-1918.
[126]Gross GJ,Peart JN.KATP channels and myocardial preconditioning:an update.AmJP siol Heart Circ P siol 2003;285:H921-930.
[127]Yan H,Du J,Tang C.The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem Biops Res Commun 2004;313:22-27.
[128]Thong C,Chen F,Cheng Y,Tang C,Du J.The role of drogen sulfide generation in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide syntllase.J Hypertens 2003;21:1879-1885.
[129]Chunyu Z,Junbao D,Dingfang B,Hui Y,Xiuying T,Chaoshu T.The regulatory effect of undrogen sulfide on hypoxic pulmonary hypertension in rats.Biochem Biopihys Res Commun 2003;302:810-816.
[130]Chen X,Du J,Zhang C, Tang C,Zhou W.Effect gaseous signal molecule,on pulmonary vascular smooth of hydrogen sulfide,a new muscle cell apoptosis in rats.J Peking Univ(Health Sci)2004;36:341-344.
[131]Chen X,Du J,Zhang C,Tang C.The regulatory effect of hydrogen sulfide on pulmonary artery proliferating cell nuclear antigen and BcL-2 in hypoxic pulmonary rats.J Appl Clin Pediatr 2004;19:185-187.
[132]Li X,Du J,Tang C.Impact and vasoactive peptides of undrogen sulfide donor on pulmonary vascular struclure in rats with high:pulmonary blood flow.Acta Acad Med Sin pulmonary hypertension induced by 2006;28:159-163.
[133]Liaohui L,Junbao D,Lin S,Jian L,Xiuying T,Jianguang Q,et al. Down-regulation of endogenous hydrogen sulfide pathway in pulmonary hypertension and pulmonary vascular structural remodeling induced by high pulmonary blood flow in rats. Circ J 2005;69:1418-1424.
[134]Chunyu Z,Junbao D,Dingfang B,Hui Y,Xiuying T,Chaoshu T.The regulatory effect of undrogen sulfide on hypoxic pulmonary hypertension in rats.Biochem Biop}hys Res Commun 2003;302:810-816.
[135]Hi L,Bhatia M,Zhu YZ,Zhu YC,Ramnath RD,Wang ZJ,et al.Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. Faseb J 2005;19:1196-1198.
[136]Hao W,Zhang J,Lu Y,Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener.Embo J 2001;20:6008-6016.
[137]Chunyu Z,Junbao D,Dingfang B,Hui Y,Xiuying T,Chaoshu T.The regulatory effect of undrogen sulfide on hypoxic pulmonary hypertension in rats.Biochem Biophys Res Commun 2003;302:810-816.
[138]Chen X,Du J,Zhang C,Tang C,Zhou W.Effectgase us signal molecule,on pulmonary vascular smooth of hydrogen sulfide, a new muscle cell apoptosis in rats.J Peking Univ (Health Sci) 2004;36:341-344.
[139]Vang R.Two's company, three's a crowd:can H2S be the third endogenous gaseous transmitter Faseb J 2002; 16:1792-1798.
[140]Qingyou Z,Junbao D,Weijin Z,Hui Y,Chaoshu T,Chunyu Z.Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathway in the pathogenesis of poxic pulmonary hypertension.Biochem Biophys Res Commun 2004;317:30-37.
[141]Stary H C,Blankenhim D H,Chandler A B,et al.A definition of initial fatty streak and intermediate lesion of arteriosclerosis. Circulation,1994,89(5):2462.
[142]韩启德,文允镒.血管生物学[M].北京市：北京医科大学、中国协和医科大学联合出版社,1997：210-212.
[143]赵建宏,林琳,曹卉,等.益气活血中药防治大鼠血管内皮细胞损伤的实验研究[J].微循环学杂志,2001,21(z)：36-35.
[144]刘洪,李荣亨.气虚血瘀证与血管内皮细胞相关因子的研究进展[J].中国中医基础医学杂志,2005,11(7)：553.
[145]贾鸿魁.益气活血法为主治疗脱疽的体会[J].陕西中医,2002,23(4)：288-289.
[146]吴勇,等.黄茂多糖对糖尿病大鼠血管内皮细胞的影响[J].辽宁中医杂志,2002,29,(1)：22-23
[147]张波,郭雁冰,许继宗,等.益气活血通脉法治疗股动脉硬化症36例疗效观察[J].辽宁中医药大学学报,2012,14(10)：23-25.
[148]杨爱东,郭永洁,余星,等.益气活血通脉颗粒对动脉粥样硬化模型家兔NO、 ET、bFGF的影响[J].上海中医药大学学报,2003,17(1)：51-53.
[149]贾乘,张林,程嘉艺,等.三七抑制大鼠血栓形成实验研究[J]1中医药学刊,2001,19(2)：172-173
[150]闰彦芳,张壮,孙塑伦,等.三七总皂普及其主要成分对血管内皮细胞缺氧损伤的保护作用[J]。中国实验方剂学杂志,2002,8(1)：34-37
[151]吕志军,梁绪国.三七总皂普对血管内皮细胞凋亡及凋亡调控基因的影响[J]1中西医结合心脑血管病杂志,2005,3(11)：975-97
[2]李小鹰,王洁,何耀,范利.周围动脉硬化闭塞症在老年血脂异常人群中的现患率调查[J].中华老年心脑血管病杂志2005,2.(7)：3-4.
[3]王玉琦,叶建荣.血管外科治疗学[M].上海：上海科学技术出版社2003：13
[4]张培华,将米尔主编,临床血管外科学(第二版),科学出版社,2007：403
[5]冯有贤主编,血管外科学(第二版),1992,上海科技出版社
[6]灵枢[M].北京：人民卫生出版社,956
[7]龚庆宣.刘涓子鬼遗方[M].北京：人民卫生出版社,1955.
[8]申斗垣.外科启玄[M].北京：人民卫生出版社,1955年排印本
[9]陈文治.疡科选粹[M].上海：新中华书社,1954.
[10]李日庆主编,《中医外科学》,2007,中国中医药出版社
[11]高思敬.外科医镜[M].北京：人民卫生出版社,1955.
[12]王清任.医林改错[M].北京：人民卫生出版社,1956
[13]高秉钧.疡科心得集[M].北京：人民卫生出版社,1955.
[14]顾伯华主编.实用中医外科学.上海科学技术出版社,1985,31.
[15]王凤歧主编.中华名医特级集成.中国中医药科技出版社,1993,468.
[16]陆德明.中医外科学[M].上海：上海科学技术出版社1997：6
[17]王巧萍,黄学阳.脱疽的古文献综述[J].中医研究,2004,17(1)：57-59.
[18]张伯根等,慢性下肢动脉缺血性疾病诊疗面临的问题及发展趋势,中国实用外科杂志,1998,18(9)：518-519.
[19]赵立军,等.脱疽痛证的机理及辨证探析.北京中医,1995,(3)：13.
[20]李翠娟,烟建华,攻振东.对中医证本质研究的反思.中国中医基础医学杂志.2005；11(4)：271-274.
[21]阎莉,吴圣贤.中医证本质研究思考.中国中西医结合杂志.2000；20(5)：383.
[22]包祖晓,刘素芝,张远怀.缺血性中风气虚血瘀证的客观化研究现状与展望.中华中医药学刊.2007；25(2)：295-298.
[23]王丽英,张宏敏,谢春光,等.中医释义动脉粥样硬化及2型糖尿病.时珍国医国药.2005；16(7)：662-664.
[24]尚德俊,王嘉桔,王书桂.中西医结合周围血管疾病学.海口：南海出社,1995：19-22.
[25]素问[M].北京：人民卫生出版社,1956.
[26]医林改错[M].上海：新中华书社,1954.
[27]素问[M].北京：人民卫生出版社,1956.
[28]鲍相敖.验方新编[M].天津：天津科学技术出版社,1991.
[29]汪机.外科理例[M].上海：商务印书馆,1957.
[30]王洪绪.外科证治全生集[M].北京：人民卫生出版社,1956.
[31]李晓亮,樊凯芳.益气活血法在闭塞性动脉硬化症中的应用[J].山西中医学院学报2006,3(5)：52-54.
[32]柳玉亭,等.中西医结合治疗闭塞性动脉粥样硬化69例.山东中医杂志1994；13(5)：211.
[33]王景春.辨证治疗肢体闭塞性动脉硬化症101例.辽宁中医杂志,1993,(11)：21.
[34]李廷来.中西医结合治疗闭塞性动脉硬化笔谈.山东医药,1984,(5)：31.
[35]宋景贵.中西医结合治疗86例闭塞性动脉硬化症的临床研究.山东中医杂志,1984,(2)：28.
[36]俞守艳,杨启发.当归四逆汤合阳和汤治疗肢端动脉硬化性闭塞症33例.实用中医药杂志,2004,20(10)：10.
[37]张建强.全元丹治疗动脉硬化性闭塞症的临床研究[J].河北中医,2001,2(12)：893-895.
[38]王书桂.益气活血法治疗动脉硬化性闭塞症的临床观察.山东中医杂志,1984,(4)：54.
[39]张氏医通[M].北京：人民卫生出版社,1956.
[40]王玉琦,叶建荣.血管外科治疗学[M].上海：上海科学技术出版社2003：11.
[41]张培华,将米尔主编,临床血管外科学(第二版),科学出版社,2007：431.
[42]王玉琦,叶建荣.血管外科治疗学[M].上海：上海科学技术出版社,2003：131.
[43]常恩坦,高桥保雄.小儿动脉粥样硬化[J].日本医学介绍,1989,10(3)：101.
[44]黄玉麟.儿童心血管疾病的危险因素[J].临床儿科杂志,1986,4(2)：85.
[45]赵亚朴.被动吸烟加速动脉粥样硬化[J].国外医学心血管分册,1999,26(1)：48.
[46]尚德俊,王嘉桔,王书桂,等.中西医结合实用周围血管疾病学[M].海口：南海出版公司,1995.179-256.
[47]Sacid B, Kryatyna TK, Juan CM,et al. Role of nitric oxide in the angiogenic response in vitro to bFGF[J]. Cire Res,1998,82(9):1007.
[48]金星,刘明,孟红等.肢体动脉粥样硬化闭塞症病毒感染相关性中医研究[J].山东中医药大学学报,2000,24(2)：101.
[49]陈瑞珍.巨细胞病毒感染与动脉粥样硬化关系的探讨[J].临床,1995,2(2)：79.
[50]冯宝根.动脉粥样硬化症与肺炎衣原体感染91例尸检结果报告[J].金陵医院学报,1999,12(2)：96.
[51]李永强,董吁钢.肺炎衣原体感染与动脉粥样硬化[J].新医学,2002,33(5)：309.
[52]Muhlestein J,AndersonJ,Hammond,et al,Infection with chlamydia pneumoniae acclerates the development of atherosclerosis and threatment with azithromycin prevents it a rabbit model[J]. Circulation,1998,97(7):633.
[53]王吉云.动脉粥样硬化与长期砷暴露有关[J].中国医学论坛报,2002,5(3)：21.
[54]李小鹰,王洁,何耀,范利.周围动脉硬化闭塞症在老年血脂异常人群中的现患率调查[J].中华老年心脑血管病杂志2005,2.(7)：3-4
[55]倪廷枢.动脉粥样硬化形成的现代观点,国外医学,老年医学分册；1997.18(1)P9.
[56]邓英姿.清道夫受体与AS关系的研究进展,国外医学,心血管疾病分册1997.24(5)P3.
[57]倪廷枢.动脉粥样硬化形成的现代观点,国外医学,老年医学分册,1997.18(1)P9.
[58]于光耀.血管内皮功能障碍与ASO中国动脉硬化杂志；1996.4(2)P145.
[59]R. ROSS Pathogenesis of atherosclerosis a perspective forthe 1990s Nature Vol 362.29 Apr1993.p801.
[60]危当恒,王贵学,黄华,刘录山,王佐,唐朝克.低密度脂蛋白对血管内皮细胞骨架及粘附能力的影响[J].医用生物学,2006,21,(6)：105-11
[61]马丽,朱文云,李宏妹,邢海燕,金永娟.OX-LDL对内皮细胞粘附分子表达及粘附功能影响的研究[J].微循环学杂志,2000.3(10)：49
[62]Sukhova GK,Babaev VR,Sirthkin Vn et al Phenotype change in smooth muscle cells or human coronary arteries during aging and during development of atherosclerosis Kardiologiia1991;31(8):15-19.
[63]Shanahan CM,Cary NR,Metcalfe JC,et al.High expression of gene for calcification regulary proteins in human athorosclerosis Plaques J Chin lnvest,1994;93(6):2393-2402.
[64]李建华,郭志刚,吴平生,杨永红,赖文岩.血管内皮细胞中ABCAI的表达及其在动脉粥样硬化发生中的意义[J].第一军医大学学报,2004,24,(9)：980-983
[65]Callow AD.Endothelial dysfunction Ⅰ natheroselerosis[J].Vascul Pharm acol,2002,38(5):257-258.
[66]Golino P,Piscione F,Willerson JT,et al.Divergent effects of serotonin on coronary artery dimensions and blood flow in Patients with coronary atheroselerosis and control patients[J].N Eng J Med,1991,324(10):641-648.
[67]LermanA,Holmes DR Jr,BellMR,et al.Endothel in incoronary endothelial dysfunetion and early atherosclerosis in humans[J].Clreulation,1995,92(9): 2426-2431.
[68]Geisler T,Bhatt DL.The role of inflammation in atherothrombosis:current and future strategies of medical treatment[J].MedSeiMonit,2004,10(12):RA308-316.
[69]Cybulsky M I,Iiyama K,Li H,et al.A major role for VCAM-1,but not ICAM-1, in early atherosclerosis[J].JClinInvest,2001,107(10):1255-1262.
[70]Boring L,Gosling J,Cleary M,et al.Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis[J]. Nature,1998,394(6696):894-897.
[71]Herman MP,Sukhova GK,Libby P,et al.ExPression of neutroPhil collage nase (matrixmetalloproteinase28) in human atheroma:a novel collagenolytic Pathway suggested by transcriptionalp rofiling[J]. Circulation,2001,104(16):1899-1904.
[72]Chamorro A.Role of inflanunation in stroke and atherothrombosis[J]. Cerebrovase D15,2004,17(Supp13):125.
[73]Becquemin JP,Favre JP,Marzelle J,et al.Systematic versusselective stent placement after superficial femoral artery balloonangioplasty:a multicenter prospective randomized study. J VascSurg,2003,37:487-494.
[74]Schillinger M,Exner M,Mlekusch W,et al.Inflammatory responseto stent implantation:differences in femoropoplitea, iliac,and carotidarteries.Radiology, 2002,224:529-535.
[75]Garasic JM,Creager MA.Percutaneous interventions for lowe extremity peripheral atherosclerotic disease.Rev Cardiovasc Med2001,2:120-125.
[76]Krishna K,Gary JB,MyriamHMG,et al.Transcatheter interventionfor the treatment of peripheral atherosclerotic lesions:Part Ⅰ.J VascInterv Radio 1,2001, 12:683-695.
[77]卢成志,David Ho,李玉光,等.髂动脉内支架植入术后临床及血管造影随访.介入放射学杂志,2002,11：182-183.
[78]Khodja HR, Sala F,Declemy S,et al.Value of stent placementduring percutaneous transluminal angioplasty of the iliac arteries. JCardiovasc Surg(Torino),2001,42:369-374.
[79]Robert MC, Ian LG,Jonathan MT,et al.Angioplasty and stent placement in chronic occlusion of the superficial femoral artery.technique and results. J Vase Interv Radiol,2000,11:1009-1020.
[80]Richard RS,Jeanine MC,Justin MG,et al.Long-term results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery:single center experience from a prospective, randomized trial.Cardiovasc Interv Radiol,2003, 14:303-311.
[81]CejnaM, Thurnher S,Illiasch H,et al.PTA versus Palmaz stent placement in femoropopliteal artery obstructions:a multicenter prospective randomized study. J Vasc Interv Radiol,2001,12:23-31.
[82]Pozzi Mucelli F, Fisicaro M,Calderan L,et al.Percutaneou revascularization of femoropopliteal artery disease.PTA plus stent Results after six years'follow-up. Radiol Med(Torino),2003,105339-349.
[83]Timaran CH,Stevens SL,FreemanMB,et al.Predictors for adverseoutcome after iliac angioplasty and stenting for limb-threateningischemia.J Vasc Surg,2002, 36:507-513.
[84]HenryM,Henry I,Klonaris C,et al.Clinical experience with the OptiMed sinus stent in the peripheral arteries.J Endovasc Ther,2003,10:772-779.
[85]金龙,邹英华,高健,等.慢性长段髂动脉闭塞的血管腔内成形治疗.中国医学影像技术,2001,17：1033-1045.
[86]Klinkert P.Schepers A,Burger DH,et al.Vein versus polytetraflu-oroethylene in above-knee femoropopliteal bypass grafting:five-yearresults of a randomized controlled trial[J].J Vase Surg,2003,37(1):149-155
[87]Ballotta E,Renon L,Toffano M,et al.Prospective randomized study onbilateral above-knee femoropopliteal revascularization:Polytetrafluo-roethylene graft versus reversed saphenous vein[J].J Vase Surg,2003,38(5):1051-1055.
[88]Sala F,Hassen-Khodja R,Lecis A,et al.Long-term outcome of femoral above-knee popliteal artery bypass using autologous saphenous vein versus expanded polytetrafluoroethylene grafts[J].Ann Vase Surg,2003,17(4):401-407.
[89]Mamode N,Scott RN.Graft type for femoro-popliteal bypass surgery [J].Cochrane Database Syst Rev,2000,(2):CD001487.
[90]Devine C,McCollum C.North West Femoro-Popliteal Trial Partici-pants. Heparin-bonded Dacron or polytetrafluorethylene for femoropopliteal bypass: five-year results of a prospective randomized multicenter clinical trial[J].J Vase Surg,2004,40(5):924-931.
[91]ZhangQinyou, Du Junbao,ZhangQunyu, et al.Impact of endogenous nitric oxide on the hydrogen sulfide/cystathionine-y-lyase system in pulmonary hypoxic rats.J Appl Clin Pediatr,2003,18:865-867
[92]金红芳,杜军保,唐朝枢.气体信号分子在心血管疾病发病中的意义.中国医学科学院学报,2005；25(2)：518-524.
[93]杜军保,齐建光,石云,等,肺动脉高压形成机制中的气体信号分子网络,北京 大学学报(医学版)2002；34(5)：536-541
[94]耿彬,闫辉,钟光珍,等.硫化氢一心血管功能调节的新型气体信号分子,北京大学学报(医学版)2004；36(1)：106.
[95]曹建春,张东萍.中西医结合治疗糖尿病足.中医药学刊,2006,24(5)：858-859.
[96]Du JB,Yan H.Cheung Y,et al.Th e possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. Heart Vessels, 2004,19(2):75.
[97]欧阳秋芳,谢良地,苏津自.内源性H2S的生理、病理功能及其与NO、CO的相互作用,中国分子心脏病学杂志,2005,5(2)：503-506.
[98]谷万里,史载祥,气体信号分子与活血化瘀研究,中国中西医结合杂志,2006,36(3)：262-265.
[99]尹小川,刘健康,周序珑,等.三七总皂贰对培养的猪主动脉内皮细胞释放一氧化氮的影响[J].中国动脉硬化杂志,1996,4(1)：20-23.
[100]Lee SW,Hu Y S,Hu L F,et al.Hydrogen sulphide regulates calcium homeostasis in microglial ceils[J].Glia,2006.54(2):116-124.
[101]Ying-Yuan Pamela Mok,Mohammed Shirhan Bin Moham med Atan,Cbeong Yoke Ping,et al.Role of hydrogen sulphide in haemorrhagic shock in the rat: protective effect ofinhibitors of hydrogen sulphide biosynthesis[J].BT J Pharmacol,2004,143(7):881-889.
[102]Lee SW,Hu Y S,Hu L F,et al.Hydrogen sulphide regulates calcium homeostasis in microglial ceils[J].Glia,2006.54(2):116-124.
[103]ShiLin,Du Junbao, Qi Jianguang,et al.Effects of L-arginine on pathologic structure and endogenous hydrogen sulfide pathway in rats with pulmonary hypertension induced by high pulmonary blood flow.Basicmedical science and clinics,2004,24:184-187.
[104]Chen Xiaobo, Du Junbao, Gen bin. Changes in arterial hydrogen sulfide content during septic shock and endotoxin shock in rats. Basic medical science and clinics,2003,23:384-387.
[105]Marika Coilin, Farhana B M. Anuar, Oliver Murch, et al. Inhibition of endogenous hydrogen sulfideformation reduces the organ injury caused by endotoxemia[J].BT J Pharmacol,2005,146(4):498-505
[106]汪德清,沈文梅.黄茂三种提取成分对氧自由基作用的影响[J].中国药理学通报,1994,20(2)：129-132
[107]Warenycia MW,Goodwin LR,Benishin CC Reiffenstein RJ,Francom DM,Taylor JD,et al. Acute hydrogen sulfide poisoning. Demonstration of selective uptake of sulfide by the brainstem by measurement of brain sulfide levels. Biochem Phannacol 1989;38:973-981.
[108]Goodwin LR,Francom D,Dieken FP,Taylor JD, Warenycia MW,Reiffenstein RJ,et al. Determination of sulfide in brain tissue by gas dialysision chromatography:postnnortem studies and two case reports. J Anal Toxicol 1989;13:108-109.
[109]Vang R.Two's company,three's a crowd:can H2S be the third endogenous gaseous transmitter Faseb J 2002;16:1792-1798.
[110]Hao W,Zhang J,Lu Y,Wang R.The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener.Embo J 2001;20:6008-6016.
[111]Abe K,Kimura H.The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 1996;16:1066-1071.
[112]Hosoki R, Matsuki N,Kimura H.The possible role of drogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem Biophys Res Commun 1997;237:527-531.
[113]Kamoun P.Endogenous production of hydrogen sulfide in mammals. Amino Acids 2004;26:243-254.
[114]Zhao W,Ndisang JF,Wang R. Modulation of endogenous production of H2S in rat tissues. Can J P siol Pharmacol 2003;81:848-853.
[115]Chen P,Poddar R,Tipa EV,Dibello PM,Moravec CD,Robinson K,et al.Homocysteine metabolism in cardiovascular cells and tissues:implications for hype;rhomocysteinemia and cardiovascular disease.Adv Enzyme Regul 1993; 39:93-109.
[116]Tang C,Li X,Du J.Hydrogen sulfide as a new endogenous gaseous transmitter in the cardiovascular system. Curr Vasc Pharmacol 2006;4:17-22.
[117]Furne J,Springfield J,Koenig T,DeMaster E,Levitt MD.Oxidation of drogen sulfide and methanethiol to thiosulfate by rat tissues:a specialized function of the colonic mucosa.Biochem Pharmacol 2001;62:255-259.
[118]Geng B,Yang J,Qi Y,Zhao J,Pang Y,Du J,et al.H2S generated by heart in rat and its erects on cardiac function.Biochem Biophys Res Commun 2004; 313:362-368.
[119]Yang q Cao K,Wu L,Wang R.Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1 J Biol Chem 2004;279:49199-49205.
[120]Du J,Hui Y,Cheung Y,Bin C,Jiang H,Chen X,et al.The possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. Heart Vessels 2004;19:75-80.
[121]Gang q Sun X,Wang R.Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen-activated protein kinases and caspase-3.Faseb J 2004;18:1782-1784.
[122]Lieng B,Chang L,Pan C,Qi Y.Zhao J,Pang Y,et al.Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol.Biochem Biophys Res Commun 2004;318:756-763.
[123]Fivarajah A,McDonald MC, Thiemermann C.The production of hydrogen sulfide limits myocardial ischemia and reperfusion injury and contributes to the cardioprotective effects of preconditioning with endotoxin, but not ischemia in the rat. Shock 2006;26:154-161.
[124]Pan TT,Feng ZN,Lee SW,Moore PK, Bian JS.Endogenous hydrogen sulfide conltributes to the cardioprotection by metabolic inhibition preconditioning in the rat venl: ricular myocytes.J Mol Cell Cardiol 2006;40:119-130.
[125]Bolli R.Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research.J Mol Cell Cardiol 2001;33:1897-1918.
[126]Gross GJ,Peart JN.KATP channels and myocardial preconditioning:an update.AmJP siol Heart Circ P siol 2003;285:H921-930.
[127]Yan H,Du J,Tang C.The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem Biops Res Commun 2004;313:22-27.
[128]Thong C,Chen F,Cheng Y,Tang C,Du J.The role of drogen sulfide generation in the pathogenesis of hypertension in rats induced by inhibition of nitric oxide syntllase.J Hypertens 2003;21:1879-1885.
[129]Chunyu Z,Junbao D,Dingfang B,Hui Y,Xiuying T,Chaoshu T.The regulatory effect of undrogen sulfide on hypoxic pulmonary hypertension in rats.Biochem Biopihys Res Commun 2003;302:810-816.
[130]Chen X,Du J,Zhang C, Tang C,Zhou W.Effect gaseous signal molecule,on pulmonary vascular smooth of hydrogen sulfide,a new muscle cell apoptosis in rats.J Peking Univ(Health Sci)2004;36:341-344.
[131]Chen X,Du J,Zhang C,Tang C.The regulatory effect of hydrogen sulfide on pulmonary artery proliferating cell nuclear antigen and BcL-2 in hypoxic pulmonary rats.J Appl Clin Pediatr 2004;19:185-187.
[132]Li X,Du J,Tang C.Impact and vasoactive peptides of undrogen sulfide donor on pulmonary vascular struclure in rats with high:pulmonary blood flow.Acta Acad Med Sin pulmonary hypertension induced by 2006;28:159-163.
[133]Liaohui L,Junbao D,Lin S,Jian L,Xiuying T,Jianguang Q,et al. Down-regulation of endogenous hydrogen sulfide pathway in pulmonary hypertension and pulmonary vascular structural remodeling induced by high pulmonary blood flow in rats. Circ J 2005;69:1418-1424.
[134]Chunyu Z,Junbao D,Dingfang B,Hui Y,Xiuying T,Chaoshu T.The regulatory effect of undrogen sulfide on hypoxic pulmonary hypertension in rats.Biochem Biop}hys Res Commun 2003;302:810-816.
[135]Hi L,Bhatia M,Zhu YZ,Zhu YC,Ramnath RD,Wang ZJ,et al.Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. Faseb J 2005;19:1196-1198.
[136]Hao W,Zhang J,Lu Y,Wang R. The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel opener.Embo J 2001;20:6008-6016.
[137]Chunyu Z,Junbao D,Dingfang B,Hui Y,Xiuying T,Chaoshu T.The regulatory effect of undrogen sulfide on hypoxic pulmonary hypertension in rats.Biochem Biophys Res Commun 2003;302:810-816.
[138]Chen X,Du J,Zhang C,Tang C,Zhou W.Effectgase us signal molecule,on pulmonary vascular smooth of hydrogen sulfide, a new muscle cell apoptosis in rats.J Peking Univ (Health Sci) 2004;36:341-344.
[139]Vang R.Two's company, three's a crowd:can H2S be the third endogenous gaseous transmitter Faseb J 2002; 16:1792-1798.
[140]Qingyou Z,Junbao D,Weijin Z,Hui Y,Chaoshu T,Chunyu Z.Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathway in the pathogenesis of poxic pulmonary hypertension.Biochem Biophys Res Commun 2004;317:30-37.
[141]Stary H C,Blankenhim D H,Chandler A B,et al.A definition of initial fatty streak and intermediate lesion of arteriosclerosis. Circulation,1994,89(5):2462.
[142]韩启德,文允镒.血管生物学[M].北京市：北京医科大学、中国协和医科大学联合出版社,1997：210-212.
[143]赵建宏,林琳,曹卉,等.益气活血中药防治大鼠血管内皮细胞损伤的实验研究[J].微循环学杂志,2001,21(z)：36-35.
[144]刘洪,李荣亨.气虚血瘀证与血管内皮细胞相关因子的研究进展[J].中国中医基础医学杂志,2005,11(7)：553.
[145]贾鸿魁.益气活血法为主治疗脱疽的体会[J].陕西中医,2002,23(4)：288-289.
[146]吴勇,等.黄茂多糖对糖尿病大鼠血管内皮细胞的影响[J].辽宁中医杂志,2002,29,(1)：22-23
[147]张波,郭雁冰,许继宗,等.益气活血通脉法治疗股动脉硬化症36例疗效观察[J].辽宁中医药大学学报,2012,14(10)：23-25.
[148]杨爱东,郭永洁,余星,等.益气活血通脉颗粒对动脉粥样硬化模型家兔NO、 ET、bFGF的影响[J].上海中医药大学学报,2003,17(1)：51-53.
[149]贾乘,张林,程嘉艺,等.三七抑制大鼠血栓形成实验研究[J]1中医药学刊,2001,19(2)：172-173
[150]闰彦芳,张壮,孙塑伦,等.三七总皂普及其主要成分对血管内皮细胞缺氧损伤的保护作用[J]。中国实验方剂学杂志,2002,8(1)：34-37
[151]吕志军,梁绪国.三七总皂普对血管内皮细胞凋亡及凋亡调控基因的影响[J]1中西医结合心脑血管病杂志,2005,3(11)：975-97